Celgene continues commitment to patient responsibility
In fact, this commitment earned Celgene the number-one spot in the recent STAR Advocacy Report, which ranks and compares companies in various sectors.
“Year after year, we continue to invest in research and development at an industry-leading pace to deliver more transformational medicines to more patients worldwide,” Zeba Khan, Celgene's vice president of corporate responsibility, said. “We also work with patient advocates, doctors, health care providers, payers and policymakers to ensure patients have affordable access to the medications they need.”
Company officials said 30 percent of Celgene's profits from the past six years has gone back into the company's research and development projects and that 60 cents of every one of those dollars has gone toward development of new therapies.
Celgene also offers Celgene Patient Support, which has helped more than 50,000 patients get access to needed therapies since its inception in 2007. The company sends teams to the Leukemia and Lymphoma Society’s Light The Night Walks, the Pancreatic Cancer Action Network’s Purple Strides campaign and the National Psoriasis Foundation Walks.
“At Celgene, we take our corporate responsibility seriously and continuously striving (sic) to advance medical innovation to benefit patients, the health care system and society,” Khan said.
Presently, Celgene's researchers are working on 18 phase III programs, with 26 treatments in clinical trials and 30 programs in pre-clinical development. More than 700 ongoing clinical trials for potential therapies are underway.
Organizations in this story
Celgene Corporation 86 Morris Ave Summit, NJ 07901